Comparison of the Ocular Hypotensive Efficacy of Adjunctive Brimonidine 0.15% or Brinzolamide 1% in Combination with Travoprost 0.004%

Ophthalmology

Volumn 114, Issue 7, 2007, Pages

  Feldman, Robert M ^a,b   Tanna, Angelo P ^c   Gross, Ronald L ^d   Chuang, Alice Z ^a   Baker, Laura ^b   Reynolds, Adam ^e   Prager, Thomas C ^a,b  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b Hermann Eye Center   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHAGAN P; BRIMONIDINE; BRINZOLAMIDE; TRAVOPROST; UNCLASSIFIED DRUG;

ADULT; ADVERSE OUTCOME; AGED; ARTICLE; BLOOD PRESSURE MONITORING; CIRCADIAN RHYTHM; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EXFOLIATION SYNDROME; FEMALE; HUMAN; INTRAOCULAR HYPOTENSION; INTRAOCULAR PRESSURE; MALE; MONOTHERAPY; MULTICENTER STUDY; OPEN ANGLE GLAUCOMA; OUTCOME ASSESSMENT; PARALLEL DESIGN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 34347240025     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ophtha.2007.03.012     Document Type: Article

References (21)

1. Kass M.A., Heuer D.K., Higginbotham E.J., et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 120 (2002) 701-713 discussion 829-30
2. Lichter P.R., Musch D.C., Gillespie B.W., et al. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology 108 (2001) 1943-1953
3. AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 130 (2000) 429-440
4. Leske M.C., Heijl A., Hussein M., et al. Factors for glaucoma progression and the effect of treatment: the Early Manifest Glaucoma Trial. Arch Ophthalmol 121 (2003) 48-56
5. Shoji N., Ogata H., Suyama H., et al. Intraocular pressure lowering effect of brinzolamide 1.0% as adjunctive therapy to latanoprost 0.005% in patients with open angle glaucoma or ocular hypertension: an uncontrolled, open-label study. Curr Med Res Opin 21 (2005) 503-508
6. Kimal Arici M., Topalkara A., and Guler C. Additive effect of latanoprost and dorzolamide in patients with elevated intraocular pressure. Int Ophthalmol 22 (1998) 37-42
7. Vanlandigham B.D., and Brubaker R.F. Combined effect of dorzolamide and latanoprost on the rate of aqueous humor flow. Am J Ophthalmol 126 (1998) 191-196
8. Erdogan H., Toker I., Arici M.K., et al. A short-term study of the additive effect of latanoprost 0.005% and brimonidine 0.2%. Jpn J Ophthalmol 47 (2003) 473-478
9. Lee D.A., and Gornbein J.A. Effectiveness and safety of brimonidine as adjunctive therapy for patients with elevated intraocular pressure in a large, open-label community trial. J Glaucoma 10 (2001) 220-226
10. Gordon M.O., Kass M.A., and Ocular Hypertension Treatment Study Group. The Ocular Hypertension Treatment Study: design and baseline description of the participants. Arch Ophthalmol 117 (1999) 573-583
11. Shin D.H., Feldman R.M., Sheu W.P., and Fixed Combination Latanoprost/Timolol Study Group. Efficacy and safety of the fixed combinations latanoprost/timolol versus dorzolamide/timolol in patients with elevated intraocular pressure. Ophthalmology 111 (2004) 276-282
12. Asrani S., Zeimer R., Wilensky J., et al. Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma. J Glaucoma 9 (2000) 134-142
13. Nouri-Mahdavi K., Hoffman D., Coleman A.L., et al. Predictive factors for glaucomatous visual field progression in the Advanced Glaucoma Intervention Study. Ophthalmology 111 (2004) 1627-1635
14. Orzalesi N., Rossetti L., Bottoli A., and Fogagnolo P. Comparison of the effects of latanoprost, travoprost, and bimatoprost on circadian intraocular pressure in patients with glaucoma or ocular hypertension. Ophthalmology 113 (2006) 239-246
15. Parrish R.K., Palmberg P., Sheu W.P., and XLT Study Group. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol 135 (2003) 688-703
16. Tsukamoto H., Noma H., Matsuyama S., et al. The efficacy and safety of topical brinzolamide and dorzolamide when added to the combination therapy of latanoprost and a beta-blocker in patients with glaucoma. J Ocul Pharmacol Ther 21 (2005) 170-173
17. O'Connor D.J., Martone J.F., and Mead A. Additive intraocular pressure lowering effect of various medications with latanoprost. Am J Ophthalmol 133 (2002) 836-837
18. Konstas A.G., Karabatsas C.H., Lallos N., et al. 24-hour intraocular pressures with brimonidine purite versus dorzolamide added to latanoprost in primary open-angle glaucoma subjects. Ophthalmology 112 (2005) 603-608
19. Reis R., Queiroz C.F., Santos L.C., et al. A randomized, investigator-masked, 4-week study comparing timolol maleate 0.5%, brinzolamide 1%, and brimonidine tartrate 0.2% as adjunctive therapies to travoprost 0.004% in adults with primary open-angle glaucoma or ocular hypertension. Clin Ther 28 (2006) 552-559
20. Sharpe E.D., Day D.G., Beischel C.J., et al. Brimonidine purite 0.15% versus dorzolamide 2% each given twice daily to reduce intraocular pressure in subjects with open angle glaucoma or ocular hypertension. Br J Ophthalmol 88 (2004) 953-956
21. American Academy of Ophthalmology. Primary open-angle glaucoma. Preferred practice pattern (2005), American Academy of Ophthalmology, San Francisco. http://www.aao.org/ppp Available at: http://www.aao.org/ppp. Accessed April 23, 2007